IAVI

💭 "As some in the U.S. contemplate stepping back from the country’s longtime role as a champion for global health, this risks reversal of decades of hard-won gains. Nor will the dangers be limited to countries on the other side of the world. Viruses do not recognize national borders." In a recent article, Wafaa El-Sadr (IAVI board member and director of ICAP at Columbia University) and Ayman El-Mohandes (dean of CUNY Graduate School of Public Health and Health Policy) call on us to remember the COVID-19 pandemic and the critical lessons learned. As new outbreaks of the dangerous #Marburgvirus and #Sudanvirus continue to flare up, investing in global health security remains absolutely crucial. Read their commentary: https://lnkd.in/dPbQpADf #PandemicPreparedness #OutsmartEpidemics

💡A call to the EU: Investing in Global Health R&D Delivers Huge Returns 🌍💶 Over the last 20 years, investments in neglected disease R&D have saved millions of lives and generated significant economic returns for the countries that have funded these innovations. #TeamEurope has been a leader in this space, driving billions in economic benefits, job creation, and knowledge spillover. Our fantastic analyst Dr Céline Aerts presented the investment case for the EU at the IAVI partner meeting in Amsterdam today and called for sustained progress with: ✅ A balanced investment strategy (push & pull mechanisms) ✅ Consistent funding across the R&D cycle ✅ Stronger coordination & streamlined access to funds Let’s keep up the momentum! Global health R&D is an investment in lives, economies, and innovation. 🔗 Learn more: https://lnkd.in/euMkXj4f #GlobalHealth #Investment #Innovation #NeglectedDiseases #Impact

IAVI was delighted to host Dr. Takanori (Taka) Funaki, chief of the Center for Research Planning and Coordination at Japan’s National Institute of Infectious Diseases, now part of the Japan Institute for Health Security, last month. Funaki was the inaugural participant in our joint Human Resource Development Program, created after IAVI and NIID signed a 2023 MoU with the goal of providing valuable scientist exchange opportunities. Funaki spent one week at IAVI’s US hub, with a stop at our Vaccine Design and Development Lab, to learn how IAVI manages different stages of the vaccine R&D cycle. He then traveled to IAVI’s South Africa hub to gain firsthand experience in clinical trial operations. 📣 "The newly established JIHS places significant emphasis on end-to-end R&D of vaccines and therapeutics. Observing IAVI’s execution helped us understand the essential divisions, components, and prioritization strategies necessary for effective R&D," said Funaki. Following this successful pilot, IAVI hopes to continue learning from our colleagues by expanding the Human Resource Development Program alongside the new JIHS! Read about the program, including a Q&A with Funaki: https://lnkd.in/eVQCXNsg

IAVI remains gravely concerned about the harm to HIV prevention research caused by the dissolution of USAID and significant cuts to the federal funding that has supported this life-saving research for decades.

Following #WorldTBDay this week, learn more about IAVI's commitment to delivering on the promise of a new tuberculosis vaccine. Last month, we shared that the first doses of the exciting vaccine candidate MTBVAC were administered in the IMAGINE clinical trial. This large-scale efficacy trial will enroll 4,300 participants in South Africa, Kenya, and Tanzania. Why MTBVAC? ★ BCG offers limited protection in adolescents and adults. ★ Single-shot candidate developed with access and affordability in mind. ★ The only live-attenuated M.tb vaccine in current trials. ★ Backed by 25 years of innovative R&D, including robust safety and immunogenicity data from Phase 1 and 2 clinical studies. Resources: 📝 https://lnkd.in/ezcAAq8u ▶️ https://lnkd.in/ezfFK4_x More below 👇 Biofabri | ZENDAL | Universidad de Zaragoza | Gates Foundation | Open Philanthropy | KfW #YesWeCanEndTB #CommitInvestDeliver

"To definitively turn the tide on #TB, many experts concur we will need an effective vaccine." Ahead of #WorldTBDay, IAVI's Elana Van Brakel accompanied Spotlight to visit the Be Part clinical research center in Paarl, South Africa — where the first doses of MTBVAC were administered in the IMAGINE clinical trial last month. The large-scale Phase 2b trial is taking place in three countries and will test the efficacy of one of the most promising TB vaccine candidates in development. This article from Spotlight highlights the researchers, participants, and partners who are instrumental to conducting the IMAGINE trial. Take a closer look 🔎 https://lnkd.in/exsbeEBz Biofabri | Universidad de Zaragoza | Open Philanthropy | Gates Foundation | KfW #EndTB

📣 "The test of our generation is not whether we can end TB, but whether we will." ☀️ Yesterday, on a sunny Westminster morning, we hosted our World TB Day Reception. We were joined by a fantastic panel: Minister Catherine West, Dineo Mathlako, CDFA (Deputy High Commissioner, South African High Commission), Eliud Wandwalo (Head of TB, The Global Fund), Kinz ul Eman (DOPASI Foundation), Dr Jessica Potter (UKAPTB) and Dr Kundai Chinyenze (IAVI). 🎯 Each speaker provided insight and inspiration: insight into the ongoing battle to end TB, and inspiration to keep fighting towards that target. Thank you, also, to our chair, Lord Nick Herbert, who offered his valuable perspective into how best to develop the political will to end TB. #WorldTBDay #YesWeCanEndTB Kitty Arie, Vincent Wooding, Sahera Ramzan, Aqsa Shah, Tanya Maxine Chinowaita, Action for Global Health, Lonna Milburn, Ph.D, R.N.

🌍 It’s #WorldTBDay, and we need a new vaccine for the world’s deadliest infectious disease. Tuberculosis (TB) caused 1.25 million deaths in 2023 despite existing treatment options.  A safe and effective vaccine would be a powerful tool to drive down #TB infections, morbidity, and deaths in high-burden countries and communities. Currently, there is only one licensed vaccine for TB: BCG, which was developed over 100 years ago and is only effective in children. It offers limited protection for adolescents and adults. The need for a new vaccine to augment the narrow protection offered by BCG is urgent. That’s why we were so excited to announce the kickoff of IAVI’s large-scale efficacy trial for MTBVAC, one of the most promising TB vaccine candidates in development today. ▶️ Learn more about MTBVAC and the IMAGINE clinical trial! Watch this video with commentary from IAVI staff. Biofabri | ZENDAL | Universidad de Zaragoza #EndTB #VaccinesWork

Journey back to 1921, a time before the internet, commercial air travel, and the discovery of penicillin. This was the year the bacillus Calmette Guérin vaccine, or BCG, was first administered to protect children against tuberculosis (TB). While those other technologies have evolved, BCG remains the only available TB vaccine. But there’s a catch – BCG doesn’t prevent TB in adolescents and adults who are most at risk of spreading and developing the disease As the world marks #WorldTBDay, IAVI's Shaun Palmer examines progress to bring about new TB vaccines 100 years after BCG in the latest article for Vaccines Today. https://lnkd.in/dkxHgyKU

IAVI congratulates John Green on the publication of "Everything is Tuberculosis" ahead of #WorldTBDay. This new book further sheds light on the world's deadliest infectious disease and is an urgent reminder that we need adequate funding and resources to strengthen TB treatment and prevention efforts. Thankfully, there are some promising TB vaccine candidates in the pipeline. Read about the IAVI-sponsored #MTBVAC, which just entered a Phase 2b clinical trial in South Africa, Kenya, and Tanzania 👉 https://lnkd.in/ezcAAq8u And listen to the below episode for more on the public health impact of TB.